Back to results
US 6,958,334 B2Granted
Inhibitors of Akt activity
AssigneesMerck & Co., Inc., Merck Sharp & Dohme Corp.
InventorsAndrew Pate Owens, Stanley F. Barnett
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds comprising a triazolo[4,3-b]pyridazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention
Claims6
A compound of the formula A:
- wherein
- R1 represents phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted with one, two or three substituents, independently selected from:
- a) halogen;
- b) C1-4 alkyl;
- c) C1-4 alkoxy;
- d) cyano;
- e) di(C1-4 alkyl)amino;
- f) hydroxy;
- R2 represents amino-C1-6 alkyl, C1-4 alkylamino-(C1-6)alkyl, di(C1-4 alkyl)amino-(C1-6)alkyl;
- R3 represents hydrogen or C1-6 alkyl;
- and
- R4 independently represents hydrogen, C1-6-alkyl, halogen, HO— or C1-6 alkyl-O;
- r is 0, 1 or 2;
- or a pharmaceutically acceptable salt or stereoisomer thereof.
11 more elements
Dependencies are inferred from the claim text.